The Prostate · 2015 · 52 citations · 28 references
PharmacyOncologyPharmacologyDrug DeliveryMetastasisTargeted Drug DeliveryCancer Drug DeliveryDrug EncapsulationLiposomal FormulationsLiposome-based DeliveryMetastatic Disease TreatmentNanocarriers For TherapeuticsLiposomal Delivery SystemsLiposomal NanocarriersLiposome Delivery SystemsLiposome Drug DeliveryLiposomesTargeted LiposomesTumor LocalizationTumor-targeted Drug Delivery
BACKGROUND: The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases. METHODS: Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growth was monitored by bioluminescent imaging. RESULTS: Intravenously administered liposomes localize efficiently to bone metastases in vivo and treatment of established bone metastases with (liposomal) dexamethasone resulted in a significant inhibition of tumor growth up to 26 days after initiation of treatment. Furthermore, 1.0 mg/kg liposomal dexamethasone significantly outperformed 1.0 mg/kg free dexamethasone, and was found to be well-tolerated at clinically-relevant dosages that display potent anti-tumor efficacy. CONCLUSIONS: Liposomal delivery of the glucocorticoid dexamethasone inhibits the growth of malignant bone lesions. We believe that liposomal encapsulation of dexamethasone offers a promising new treatment option for advanced, metastatic prostate cancer which supports further clinical evaluation.
28
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek Arora, Emily Schenkein, Rajmohan Murali et al. · Cell · 2013 · 996 citations · Full text
Chaoying Liu, Juan-Ying Xu, Xiaoyan Shi et al. · Laboratory Investigation · 2013 · 461 citations · Full text
Life Sciences, Immunology, Oncology +17